Eton PharmaceutcialsETON
ETON
About: Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Employees: 31
0
Funds holding %
of 7,323 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
136% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 11
87% more call options, than puts
Call options by funds: $891K | Put options by funds: $476K
32% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 22
21% more funds holding
Funds holding: 70 [Q4 2024] → 85 (+15) [Q1 2025]
3.35% more ownership
Funds ownership: 49.31% [Q4 2024] → 52.66% (+3.35%) [Q1 2025]
5% more capital invested
Capital invested by funds: $175M [Q4 2024] → $183M (+$8.36M) [Q1 2025]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q4 2024] → 1 (-1) [Q1 2025]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$26
79%
upside
Avg. target
$30
104%
upside
High target
$35
141%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth | 141%upside $35 | Buy Maintained | 29 May 2025 |
B. Riley Securities Madison El-Saadi | 79%upside $26 | Buy Reiterated | 16 May 2025 |
Craig-Hallum Chase Knickerbocker | 93%upside $28 | Buy Maintained | 14 May 2025 |
Financial journalist opinion
Based on 3 articles about ETON published over the past 30 days
Neutral
GlobeNewsWire
2 days ago
Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025
DEER PARK, Ill., July 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report second quarter 2025 financial results on Thursday, August 7, 2025. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).
Positive
Seeking Alpha
2 weeks ago
Eton Pharma Near Term Catalysts Vanish
Important near-term catalysts for ETON have been eliminated due to insider stock sales and a disappointing partial FDA approval for their new drug, Khindivi. Insider sales by the CEO and CBO after Q1 2025 earnings suggest no imminent M&A activity and have dented investor confidence. Khindivi's FDA approval excluded the key under-5 age group, removing the potential for a Khindivi driven near-term revenue guidance beat.
Neutral
GlobeNewsWire
3 weeks ago
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)
- NDA assigned a Target Action Date of February 25, 2026 -- Product has patent protection through 2044 - DEER PARK, Ill., July 08, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the Company's New Drug Application (NDA) for ET-600, a proprietary patented formulation of desmopressin oral solution, has been accepted for review by the U.S. Food and Drug Administration (FDA) and has been assigned a Prescription Drug User Fee Act (PDUFA) target action date of February 25, 2026.
Neutral
GlobeNewsWire
1 month ago
Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes
DEER PARK, Ill., June 27, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will be added to the broad-market Russell 3000® and small-cap Russell 2000® Indexes, effective after the U.S. market closes on June 27, as part of the 2025 Russell Indexes reconstitution.
Positive
Seeking Alpha
1 month ago
Eton Pharmaceuticals: Rapid Revenue Growth And Pipeline Catalysts Point To More Upside
Eton Pharmaceuticals is experiencing explosive rare-disease revenue growth, with a 117% YoY increase and a robust pipeline fueling future expansion. Despite a 400% share price surge, ETON remains attractively valued versus peers, offering high growth potential for risk-tolerant investors. Operational leverage is improving, and near-term catalysts—product launches, label expansions, and M&A—could drive further upside as profitability approaches.
Positive
Zacks Investment Research
1 month ago
Eton Pharmaceuticals (ETON) Upgraded to Buy: Here's Why
Eton Pharmaceuticals (ETON) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Positive
Zacks Investment Research
1 month ago
Eton Pharmaceuticals (ETON) Is a Great Choice for 'Trend' Investors, Here's Why
Eton Pharmaceuticals (ETON) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
Positive
Benzinga
2 months ago
FDA Approves Eton Pharma's Oral Drug For Adrenal Insufficiency In Pediatric Patients, Analyst Sees Boost In 2025 Revenue
The U.S. Food and Drug Administration (FDA) approved Eton Pharmaceuticals, Inc.'s ETON new drug application (NDA) for Khindivi (hydrocortisone) oral solution as a replacement therapy for pediatric patients five years of age and older with adrenocortical insufficiency.
Neutral
GlobeNewsWire
2 months ago
Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI™ (hydrocortisone) Oral Solution
• KHINDIVI is the first and only FDA-approved hydrocortisone oral solution• Commercial launch expected the week of June 2nd • Eton expects combined peak sales of KHINDIVI and ALKINDI SPRINKLE® (hydrocortisone) oral granules to exceed $50 million
Positive
Seeking Alpha
2 months ago
Eton Pharmaceuticals Set To Dominate Orphan Drug Niche
Giant pharma companies are not the right owners of ultra-rare disease orphan drugs. The associated revenue streams are simply too small. ETON can acquire and develop these drugs, better serving patients and investors. The model is already working well. ETON is able to execute on straightforward product improvements, and has the focus to educate specialist doctors on the need for these rare drugs.
Charts implemented using Lightweight Charts™